Veeva Systems: A Deep Value Investing Study

Fact: customers, pricing, and cost structure. Customers are mainly pharmaceutical, biotech, medical device, and diagnostics companies. Veeva charges both for software subscriptions and for professional services such as implementation, consulting, and training. In FY2026, the subscription business had an 87% gross margin and professional services only 18%, for a total gross margin of 76%; this shows that the real value creation lies in the software and data layers, while professional services act more as enabling capabilities that drive adoption and expansion rather than the core of profit.

Fact: dependencies. Almost all of the company's revenue comes from the life sciences industry, so it is not diversified; it is directly exposed to the pharmaceutical industry cycle, the R&D funding environment, regulatory change, and industry consolidation. The company is also migrating from the legacy Veeva CRM, which depends on the Salesforce platform, to Vault CRM, built on its own Vault platform; the latest 10-K states explicitly that the legacy Veeva CRM is expected to be supported through December 31, 2029, and that if the migration fails, is delayed, or causes customer disruption, the business could be materially adversely affected.

Fact: customer concentration. Customers are highly important to Veeva, but revenue is not held hostage by any single customer. The 10-K discloses that in each year presented, no single customer contributed more than 10% of total revenue; however, accounts receivable did include a single customer exceeding 10% in FY2024 and FY2025, while in FY2026 no customer exceeded 10% of receivables. This structure means that "industry concentration" is a real risk, but "fatal dependence on a single customer" is not.

Fact and inference: the industry's stage. Life sciences is not an industry in rapid decline. IQVIA's public research holds that global drug usage and spending will still be growing through 2030; at its 2024 Investor Day, Veeva described the life sciences industry as "over $2 trillion in size, with long-term growth of 6%+," and estimated its own serviceable market at over $20 billion, with FY2025E penetration of about 14%. These figures carry a management-estimate flavor, but the direction is clear: Veeva is not facing a shrinking market but a regulation-heavy industry whose process digitization and data buildout are still deepening.

Fact: regulation and demand stability. A key source of demand for life sciences software is not "an optional efficiency tool" but compliance. The FDA's 21 CFR Part 11 applies explicitly to electronic records and electronic signatures subject to regulatory requirements, and such rules inherently demand audit trails, validation, access controls, and record integrity. For customers, this raises switching barriers and moves the software from "ordinary IT spending" closer to "operating infrastructure."

Assessment of the competitive landscape. The main competitors Veeva names in its own 10-K include IQVIA, Dassault Systèmes, Oracle, OpenText, and Honeywell, along with data-focused players such as Ipsos and Definitive Healthcare. IQVIA is the public comparable most worth weighing: its full-year 2025 revenue was $16.31 billion, Technology & Analytics Solutions revenue was $6.626 billion, adjusted EBITDA was $3.788 billion, and free cash flow was $2.051 billion, showing that it is larger and broader across life sciences technology, data, and services. By comparison, Veeva is purer, more software-centric, higher-margin, and more focused.

My judgment: This is a good company in a good industry, not an excellent company in a poor one. Long-term industry demand exists, regulation and compliance raise the importance of the software, and customers' need for process stability strengthens switching costs; but the industry is not without risk, as it is exposed to pharma budgets, policy, and technological substitution, and most competitors are large companies. Business understandability score: 4.5/5; industry attractiveness score: 4/5.

Moat and Governance

Brand advantage: medium-strong. In life sciences vertical software, Veeva's brand is not just "name recognition" but a "reputation that can be referenced in sales." The company itself writes "reference selling" into its risk factors: it relies heavily on recommendations from key customers to win new ones. Phrased the other way, the success stories of existing flagship customers are themselves a sales asset.

Switching costs: strong. Veeva's products span critical processes across clinical, quality, regulatory, commercialization, and data, and are embedded in documents, data, workflows, and compliance requirements. For customers subject to FDA and similar oversight, replacing a system is not "switching to another SaaS login screen" but often means validation, training, process redesign, and audit risk. Especially for the systems-of-record products on the Vault platform, switching costs are typically far higher than for ordinary enterprise software.

Scale advantage: strong. With 1,552 customers across four product clouds, covering everything from R&D to commercialization, plus extensive implementation experience, Veeva can build a "suite effect" within a single vertical. In 2026 the company further disclosed that more than 125 customers were live on Vault CRM, and that by year-end 10 of the top 20 biopharma companies had committed globally to Vault CRM; this density of customers and ability to execute is not something a small vendor can quickly replicate with capital alone.

Data advantage: medium-strong. Veeva does not just sell software. It has built data platforms across products such as Data Cloud, Crossix, and Compass Patient/Prescriber/National, and explicitly treats "connected reference data, deep data, and transaction data" as part of its platform capability. Once data products combine with CRM, marketing analytics, patient-journey analytics, and target identification, they reinforce customer stickiness and differentiation.

Network effects: weak to medium. Veeva is not a classic platform-network-effect company. More customers do not directly benefit each customer more, the way a social network does. Its "network effect" shows up more in accumulated data, ecosystem awareness, product-suite coverage, and industry-standardized processes, rather than in a classic two-sided network. This moat exists, but it is not the primary one.

Cost advantage: limited. Veeva's edge is not that it is "much cheaper than everyone else" but that it fits life sciences processes better, deploys faster, and passes compliance validation more easily. It behaves more like a "high-value, high-switching-cost" specialist than a low-cost supplier.

Channel and regulatory barriers: medium. On distribution, Veeva relies on direct sales, long-term customer relationships, and industry reputation; on the regulatory side, the company holds some patents and intellectual property, but the truly important barrier is not the patents themselves, rather its deep understanding of life sciences processes, validation requirements, and compliance scenarios. Its barrier leans toward "know-how plus workflow embedding" rather than pure legal exclusivity.

Corporate culture and operating capability: strong. Veeva converted to a Public Benefit Corporation in 2021 and repeatedly cites "build a lasting company" as part of its management philosophy. As a value investor, I do not automatically award a high score for this, but it at least provides two favorable signals: management publicly emphasizes long-term operations over short-term financial engineering, and this culture is consistent with its high customer stickiness, low leverage, and long-term product roadmap.

Management integrity and shareholder alignment: generally good. As of March 31, 2026, founder and CEO Peter Gassner beneficially held about 15.638 million shares, roughly 9.4% of common stock; all directors and officers together held about 10.6%. The CEO does not participate in the annual cash incentive plan and, apart from a below-market base salary, has taken essentially no cash incentives since the IPO, with long-term incentives consisting mainly of options carrying high strike prices and long vesting periods. This design clearly ties management's reward to the long-term share price and enterprise value.

Governance quality: better than a few years ago. Veeva previously had a dual-class share structure, but in October 2023 Class B converted to Class A; the 2026 proxy also lists a "single class of common stock" as one of its governance improvements. For outside shareholders, this is better than before.

Capital allocation: rational, but not perfect. The strength is that the company has long maintained a very strong net cash position with almost no interest-bearing debt, and has not pursued large, frequent, aggressive acquisitions in the name of scale. The weakness is that the timing of buybacks has not been impressive: in FY2026 the company repurchased and retired 801,700 shares at an average price of $224.43, for a total of about $179.9 million, while the current share price is only about $158.49. This suggests management may be rational on "whether to buy back" but not impressive on "at what price buybacks are optimal." For a conservative investor, this is a deduction that cannot be ignored. Moat strength score: 4/5; management and capital allocation score: 4/5.

Financial Quality and Owner Earnings

The table below uses the plainest measures that best reflect business quality to examine Veeva: revenue, margins, operating cash flow, a conservative free-cash-flow proxy, stock-based compensation, and share-count changes.

Note on methodology: Revenue, profit, cash flow, and stock-based compensation in the table all come from the GAAP figures in the company's FY2021-FY2026 annual reports and 10-Ks; the "FCF proxy" is estimated as operating cash flow minus long-term assets from the cash flow statement, because the company does not separately break out maintenance capital expenditure. This measure is usable for an asset-light software company like Veeva, but it is still an estimate, not an official management-disclosed metric.

Fact: quality of growth. From FY2021 to FY2026, revenue rose from $1.465 billion to $3.195 billion, more than doubling in five years; over the same period operating margin first climbed from 25.8% to 27.3%, then fell back in FY2023-FY2024 amid investment and accounting/business timing, before rebounding to 25.2% and 28.7% in FY2025-FY2026. This shows that Veeva is not a company that earns less as it grows; on the contrary, once scale and product maturity arrived, its profit leverage reasserted itself.

Fact: quality of cash flow. In every year from FY2021 to FY2026, operating cash flow was significantly higher than net income, with FY2026 at $1.415 billion against $909 million. Deferred revenue grew from $617 million in FY2021 to $1.489 billion in FY2026, which also shows that customer prepayments and the subscription model provide real support for cash conversion. Looking only at reported cash flow, this is a very attractive company.

But one caveat must be added immediately: stock-based compensation is a real cost. In FY2026 stock-based compensation reached $473 million, about 14.8% of revenue; in FY2023-FY2025 it was $352 million, $394 million, and $437 million respectively. At the same time, year-end shares rose from about 152.1 million in FY2021 to about 163.8 million in FY2026, an increase of roughly 7.7% over five years. This means Veeva's "reported free cash flow" is strong, but if you stand in the shoes of a per-share owner, you must acknowledge that a substantial portion of that cash flow comes from keeping shareholder dilution costs off the books.

Fact: the balance sheet. As of the end of FY2026, total assets were $8.979 billion, total liabilities only $1.765 billion, and shareholders' equity $7.215 billion; cash, cash equivalents, and short-term investments totaled about $6.56 billion, lease liabilities totaled about $96 million, and there was no substantial interest-bearing long-term debt. In short, this is an exceptionally solid balance sheet. Net debt/EBITDA is negative and the interest coverage ratio is essentially meaningless to analyze, because there is almost no debt.

Fact: working capital and accounting quality. Accounts receivable grew along with revenue, but the company discloses that no single customer contributed more than 10% of revenue in any year presented; the FY2026 receivables concentration also declined slightly from FY2024/FY2025. There is no clear sign of building cash flow by stretching payables or recognizing revenue aggressively. The company is audited by KPMG, and the proxy discloses that KPMG has audited its financial statements since FY2010. Based on public materials, I see no obvious red flags of financial fraud or aggressive accounting.

Fact and caution: tax law affects cash flow comparability. The FY2025 10-K notes that U.S. tax law requires R&D expenditure to be capitalized and amortized, which reduced current-period operating cash flow; the FY2026 10-K then notes that the OBBBA restored the option to deduct certain domestic R&D expenditure pre-tax, which will raise operating cash flow in the future. For a conservative investor, this means the OCF time series over the past two years has been distorted by tax law and cannot be extrapolated mechanically.

Owner Earnings estimate. I offer two levels. At the first level, reported FCF: FY2026 operating cash flow of $1.415 billion, minus long-term assets of $29.13 million, gives about $1.386 billion. At the second level, conservative owner earnings: on top of reported FCF, treating stock-based compensation of $473 million as an economic cost that must be borne by shareholders, gives about $913 million. I favor the second level, because it comes closer to "how much cash this company can distribute without continuously diluting shareholders." Against the current market capitalization of $26.77 billion, the current price equals about 29.3 times conservative owner earnings; if net cash is deducted to look at the operating business, the corresponding operating-value multiple is about 22 times.

My judgment: Veeva's profits are largely real cash profits, but the fact that "free cash flow is significantly higher than net income" needs to be understood with a discount, because a substantial portion of it comes from adding back stock-based compensation. It is not an accounting-illusion company, nor one that grows hungrier for cash the more it grows; it is a company where "growth generates cash," only the per-share measure is not as flawless as the reported figures appear.

Valuation and Margin of Safety

Method One: owner-earnings discount method. The valuation below starts entirely from FY2026 conservative owner earnings of $913 million, valuing the operating business first and then adding roughly $6.56 billion in cash and short-term investments as of the end of FY2026. To avoid "looking cheap by merely treating SBC as thin air," I did not use the reported FCF of $1.386 billion as the primary anchor. The starting data come from the company's FY2026 10-K and the current market capitalization/share price.

Inference: The implication of this model is straightforward: if you accept that SBC is a real economic cost, then Veeva is not particularly cheap at the current price. It sits roughly "near the lower end of the neutral value range," not "clearly below conservative value." For a conservative investor, this cannot be called a thick margin of safety.

Method Two: relative valuation method. Compared with its strongest public peer, IQVIA, Veeva is clearly more expensive today, but its asset quality is also clearly better. Roughly calculated from the current price and the latest financials: Veeva's P/E is about 30.9 times, market cap/reported FCF about 19 times, and EV/EBITDA about 21 times; IQVIA's P/E is about 20.6 times, market cap/FCF about 13.7 times, and EV/EBITDA about 11 times, but its net debt is as high as $13.74 billion, with net leverage of about 3.63 times. Put simply, Veeva should indeed enjoy a valuation premium, because it is lighter, cleaner, and more like high-quality industry software; the issue is that this premium is already quite full today.

On P/B and ROIC. Veeva's current P/B is about 3.7 times, but for a software company, P/B has very limited explanatory power. On ROIC, if the large net cash is stripped out, Veeva's cash-adjusted ROIC would be very high; but such calculations are strongly distorted by deferred revenue, the asset-light model, and excess cash, so I prefer to characterize it qualitatively as "very high and excellent" rather than offer a pseudo-precise figure that looks scientific but carries a lot of noise. By comparison, ROE and ROA are more intuitive: both FY2026 ROE and ROA sit in the excellent range.

Method Three: asset/liquidation value method. For a company like Veeva, asset-based value is quite limited. Cash and short-term investments of about $6.56 billion work out to roughly $40/share; book shareholders' equity of about $7.21 billion works out to about $44/share. But note that Veeva's liabilities include a large amount of deferred revenue, which represents future service obligations, not cash that can be freely distributed overnight. The asset method can therefore only tell us that "the floor is decent and the finances are very stable," but it cannot explain the current price of $158. The real value comes mainly from discounting more than ten years of future cash flow.

Overall valuation conclusion. The ranges I offer are: Conservative intrinsic value $135-150/share; Fair intrinsic value $160-180/share; Optimistic intrinsic value $195-215/share. At the current level of about $158.49, Veeva trades at only a small discount to "fair value," but still at a premium to "conservative value." For an investor who requires a 20%-30% margin of safety, this is nowhere near enough.

The price discipline I am willing to adopt. Ideal buy range: $125-140. This corresponds to a discount of at least about 20% to fair value, and even if growth falls short, it is less likely to suffer permanent capital loss. Acceptable holding-price range: $145-175. This range is better suited for existing holders weighing whether to keep holding, rather than for new buyers building positions aggressively. Clearly overvalued range: above $200. At this level, unless you adopt significantly more optimistic growth and margin assumptions, the reward/risk ratio worsens noticeably.

Answer on the margin of safety. The current price is not "cheap enough." The most fragile assumption in the valuation is that the market will long view Veeva as a stable high-growth company and that the Vault CRM migration completes largely smoothly. If growth falls short, margins retreat, or the market begins to re-rate it from a "high-quality vertical SaaS" into a "mature life sciences IT company," returns will come under clear pressure. The most typical risk here is precisely this: a good company, but an ordinary price.

Risks, the Bear Case, and Opportunity Cost

Competition and technology substitution risk. Veeva does not operate in a market "without rivals." In data and commercial solutions it competes with IQVIA, Ipsos, Definitive Healthcare, and others; in R&D, quality, and the platform layer it competes with Dassault, Oracle, OpenText, Honeywell, and customers' in-house solutions. AI further raises substitution risk: whoever can embed industry data, processes, and models more deeply into the business has the chance to chip away at others' barriers. Veeva currently claims it is "uniquely suited" to deliver industry AI; I think this is a reasonable direction, but it remains in the proving stage.

Risk of the business model being disrupted. The most critical issue is the CRM migration. The company writes this risk very plainly in its 10-K: Veeva CRM still depends on the Salesforce platform, and the migration to Vault CRM could cause customer disruption, performance issues, delays, and even customer attrition. In late 2025 management projected that it could retain at least 70% of biopharma CRM subscription revenue share through 2030, but this is a forward-looking management statement, not a verified fact. As soon as a clear crack appears in this migration storyline, the market will re-rate the stock.

Industry and customer risk. Almost all of Veeva's revenue comes from the life sciences industry. Pharma consolidation, tighter R&D funding, price regulation, changes in healthcare payment policy, and shifts in government-agency resources all feed through to IT spending. The company also notes explicitly in its risk factors that large-customer consolidation can reduce seat counts, compress unit prices, or weaken demand for certain solutions.

Valuation and permanent-loss risk. Veeva's biggest risk today is not a financial blowup but a contraction of the "high-quality premium." If growth slows to mid-single digits over the next three to five years, stock-based compensation stays high, and the Vault CRM migration does not clearly beat expectations, the market could de-rate it from about 31 times P/E to a more ordinary software/life sciences IT valuation. In that case, even if the company keeps making money, shareholders could endure a long stretch of low returns, even a 30%-50% drawdown.

Management and capital allocation risk. I generally trust management's long-term orientation, but I do not deify it. The FY2026 buyback average of $224.43 is well above the current share price; this at least shows that "the company is excellent" does not automatically mean "every step of capital allocation is excellent." In addition, while the CEO's long-term option incentives carry high strike prices and strong alignment, the erosion of per-share value by large stock-based compensation is real.

The strongest bear case. The bear case would go like this: Veeva is an excellent company, but the richest-dividend phase may already be behind it. The traditional CRM within the commercial business is gradually maturing, and while the new Data/AI opportunity is large, competition there is stronger; the R&D and quality clouds are steady, but moving further up runs into longer sales cycles, stronger rivals, and greater organizational complexity. At the same time, the high FCF that shareholders see is largely flattered by SBC, and the current valuation is not cheap, so buyers are taking on "a decent company plus an ordinary price plus non-trivial execution risk." I consider this not a straw-man bear case but the short thesis most worth confronting seriously today.

Which facts would overturn the investment judgment. If the following facts emerge over the next two to three years, I would admit the judgment was wrong: first, the Vault CRM migration goes significantly poorly and customer retention clearly falls short of management's claim that "most customers will migrate, with at least 70% share by 2030"; second, stock-based compensation stays high for a long time while buybacks cannot offset dilution, leaving per-share owner earnings stagnant; third, R&D/Quality cloud growth steps systematically down, indicating the company has shifted from "deep expansion" to "maintaining the installed base"; fourth, clear aggressive accounting, a major data-compliance incident, or damaged management credibility appears.

Comparison with other opportunities. Versus IQVIA, Veeva is cleaner, more focused, and more like a long-term high-quality software asset; IQVIA is cheaper but more complex and more leveraged. Versus a broad index, Veeva's potential long-term return is not without appeal, but at the current price it may not clearly beat a "more diversified, more worry-free" index. Versus the roughly 3.8%-4.0% yield on short-to-intermediate U.S. Treasuries today, Veeva of course offers more long-term compounding room, but this extra return is not large enough to make me ignore valuation discipline. For a concentrated portfolio that can hold only five assets, I would say: Veeva deserves a place in the candidate pool, but today it is not yet certain enough to make the final list.

Checklist and Final Judgment

【Final Rating】 Watch

【One-Sentence Investment Thesis】 Veeva is a high-quality, strong-cash-flow software company deeply embedded in life sciences processes, but buying at today's price offers a good win rate and an ordinary payoff.

【Core Bull Case】 The business is simple and highly sticky, subscription revenue makes up a large share, and life sciences compliance scenarios raise the difficulty of replacement. The balance sheet is exceptionally strong, with cash and short-term investments of about $6.56 billion and almost no interest-bearing debt. FY2026 operating performance was excellent, with revenue, profit, and cash flow growing in step and operating margin recovering to 28.7%. The R&D/Quality cloud and the Data/AI opportunity are still expanding, and the business mix is more diversified and steadier than a decade ago. Management's long-term orientation is fairly strong, the founder's stake is significant, and the CEO's cash incentives are extremely low.

【Core Bear Case】 The current valuation is not cheap, and the margin of safety is insufficient. The Vault CRM migration is the key execution risk that will decide success or failure over the next three to five years. Stock-based compensation is high, and reported free cash flow needs to be understood with a discount. The company is highly exposed to the life sciences industry cycle and regulatory environment. The FY2026 buyback average is well above the current price, so capital allocation is not flawless.

【Key Assumptions】 The Vault CRM migration is largely successful and customer attrition is manageable; The R&D/Quality cloud continues to maintain relatively high penetration; Stock-based compensation as a share of revenue gradually declines or is effectively offset by buybacks; The company can still sustain high-single-digit to low-double-digit owner-earnings growth over the next ten years; Investment in digitization, compliance, and data within life sciences does not reverse structurally.

【Fair Buy Price】 The more comfortable entry point I offer is $125-140/share; if you already own it, $145-175 can still be viewed as a reasonable holding range. This recommendation is not because I am bearish on the company, but because I value "buying well" more than "being slightly right."

【Target Holding Period】 Ten years or more. This is a classic company that must realize value through products, customer relationships, deep industry-cloud penetration, and per-share cash-flow compounding, and it is not suited to defining success or failure by valuation swings within 12 months.

【Expected Annualized Return】 Conservative scenario: 5%-7%; Neutral scenario: 8%-10%; Optimistic scenario: 11%-13%. These are long-term return assumptions derived from the owner-earnings discount and valuation ranges above, not market forecasts, and not short-term target-price promises.

【Maximum Loss Risk】 If the Vault CRM migration stumbles, growth slows significantly, and the market compresses the valuation from a high-quality SaaS premium back to an ordinary software/life sciences IT level, a permanent capital loss of 40%-60% in the share price is not unimaginable. The large cash position provides some cushion at the bottom, but it cannot cushion the valuation contraction that comes from "the growth thesis being disproven."

【Tracking Metrics】 I will continuously track: the number of customers live on Vault CRM; top 20 biopharma commitments and migration progress; the revenue-growth gap between Commercial Solutions and R&D/Quality Solutions; stock-based compensation as a share of revenue; year-end share-count changes; the gap between operating cash flow and conservative owner earnings; the quality of deferred revenue and accounts receivable; the commercialization pace of new data products and Veeva AI; buyback prices and amounts; and margin trends after FY2027.

【Signals That Trigger Re-Evaluation】 Management lowering its long-term statements on Vault CRM share/migration; Commercial Solutions growth persistently lagging and not being filled by R&D/Quality; SBC staying high for the long term while the share count keeps swelling; A major customer loss, regulatory event, data-compliance incident, or accounting problem; Buybacks continuing to occur in a clearly overvalued range and eroding the cash cushion.

【Final Recommendation】 Soberly put, Veeva is not a company I would dismiss lightly, but a company on which I will be strict about price. It meets the most core conditions: "understandable," "good business," "high-quality cash flow," "solid balance sheet," and "worth tracking long-term"; but for a balance-leaning-conservative investor, the most rational action today is not to rush to buy, but to place it high on the watch list and wait for a better payoff. If the price returns to the ideal range I have set, or if the facts after FY2027 further confirm a successful Vault CRM migration and steadily rising per-share owner earnings, then it could well move from "Watch" to a long-term asset genuinely worth a heavy position.

Open questions and the limits of the data: As of the current date, Veeva's FY2027 first-quarter results have not yet been released, and the company plans to disclose them on June 3, 2026; the latest full-period financial basis for this report therefore remains the FY2026 10-K and the FY2026 annual-report press release. Another limit is this: my references to market share and TAM, wherever they come from Investor Day or Recent Disclosures, should all be treated as management estimates/forward-looking statements rather than independent third-party audited conclusions.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.